-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Rigel Pharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2024.
- Rigel Pharmaceuticals Inc Operating Income (Loss) for the quarter ending December 31, 2024 was $16.7M, a 747% increase year-over-year.
- Rigel Pharmaceuticals Inc Operating Income (Loss) for the twelve months ending December 31, 2024 was $24.2M.
- Rigel Pharmaceuticals Inc annual Operating Income (Loss) for 2024 was $24.2M.
- Rigel Pharmaceuticals Inc annual Operating Income (Loss) for 2023 was -$20.5M, a 63.1% increase from 2022.
- Rigel Pharmaceuticals Inc annual Operating Income (Loss) for 2022 was -$55.6M, a 345% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)